AstraZeneca Sues Actavis Over Planned Generic Vimovo
The suit claims that Actavis' abbreviated new drug application, which it notified AstraZeneca of in March, infringes five patents covering the drug that expire between 2014 and 2023.
AstraZeneca claims that the infringement was willful and seeks a permanent injunction barring Actavis from infringing the patents.
It also asks the court to rule that the earliest date the generic version can...
To view the full article, register now.